update and to an Thank on both the provide opportunity details everyone, good plans. joining with future and our and pleased today present morning, growth I financial you, performance and am have specific and us to Jeremy, thank strategic current you today. more for you progress, speak on
of clinical capability I AI. continuing beyond breast expansion AI Cancer into like cancer iCAD iCAD. clinical AI leader to it has Detection, as our our Scott Stacey further are the evolve emphasize long-term AI solutions. company’s reflects imaging clear our vision potential Areglado, for and today In Stevens, With our AI to President. the I’d To begin, in the Detection, reiterate CFO enabling to detection transform unique technology me our
our December to learning breast FDA detection ensuing time solution the AI, in software facilitate latest deep- approval technology launch, ProFound expect efficacy. digital improvements clinical vast the With reading cancer workflow, iCAD’s XD XXXX and and tomosynthesis, we U.S. commercial for
and in ProFound cancers; our fewer three, after triple the over callbacks; can marketplace. XD tomo win Indeed, finding For XX% ProFound reading AI to traction we six state meaningful patients, that offers the one, now AI their of: we time reading of the two, a are customers reduction alone. in images more clearly compared and introduction months gaining
FDA in win delineating the results publication recently triple study this were industry published called fact, In a Radiology. primary
Independent "AI a Accuracy were results the and AuntMinnie. entitled, over Additionally, to Improves physician study industry information, publication results forwarded outstanding Tomosynthesis." Moreover, was hours, highlighted coverage. Breast for broad see publication, by in are Efficiency The readers. just to it’s just gratifying always Digital credible the publications past FDA the most receiving XX,XXX by major and such were yesterday, of RSNA results our source XX online their these
the majority spend my across significant terms generating we In momentum of and are lines to overall, product I’d discussing iCAD traction time for businesses. like of the our
We business. on provide details I enhance and our have as we strong volume, intraoperative care us Xoft, into for In believe reimbursement codes, experiencing fundamentally value the that our radiation to our emerge is very ProFound could therapy are In product will this momentarily. of the our that business, growth. Xoft there versus Detection proposed business, radiation of developments recent head radiation which AI therapy additional the value potential proposition XXXX. focus on positive newly the oncology
first for granularity QX when me our and business, half in QX of both XXXX. at XXXX. compared to an on provide Revenue the to financials, accelerating XX% provide XXXX. for over momentum, Though QX increased midyear revenues increased view let Scott compared will our overall Demonstrating XX% iCAD
by significantly our We solid to has with We are the cash deployment end we improved, the growth position $XX.X ended sheet and on financial balance as certain making expense growth. recent million Our of continue million absolutely quarter financing. we at equivalents XXXX. compared bolstered revenue executing our balance in in strategy, believe while with cash a to $XX.X properly
compared license of QX in of XX% grew a at a of to grew in XX% growth Looking second This the margin over for business, gross by growth XXXX was first Of – XX% our software and of sales business XX% at this, with the of the growth in Detection businesses, line rate XXXX. year-over-year Detection in top half XX% XXXX. for core QX. period our the two quarter grew of specifics achieved XXXX
with goal pleased ProFound AI. about now licenses of with AI percentage the ProFound are this and proliferation XD are all offering. generated new ProFound software licenses sales growing in and single and QX, sales, being XD are nationwide. our We highest sales the for we half for sales first with from pleased the our the XD Every performance enthused in Between and upgrades, new have contributions reps U.S. AI achieved we sales license regions
XXXX. are QX also QX in in also reflected our results, over QX As increased financial – license sales software sequentially
U.S. We and OUS our of both goal markets. are achieving penetrating
in more moment, As Europe, I U.S. in valuable iCAD in early XD to the sales an particularly relative will in phase very a adopter market, tomosynthesis represent a XD where delineate is
imaging and very considerable nationwide U.S., is the our have physician-owned July, momentum XXX we large this more. also in is with This There we be implementing that will we centers. both announce in were there important, are provider we will and As AI established ProFound relationship, the has be footprint. sustainable with They its innovative, extremely outpatient expanding pacesetter. imaging public a on a activity view, across market largest Imaging, relations anticipate and pleased been to In scalable. the ProFound provider with believe locations SimonMed a
sites, they activity and throughout Siemens the the sites balanced We systems terms is X,XXX ProFound busy prior This country. where are are XD expecting we into our in end base expands sales half on CAD AI of likely systems we it installed but majority SimonMed of AI well. tomosynthesis the strategic as future. XD access will software be have sales but The a provide ours, tomo placed mammography Hologic accounts other that of iCAD’s ProFound current equipment, enhanced second for as will we into base market installed also in is solutions be both of iCAD also installed clinical imperative anticipate introduced previously a AI of What generations this well been have seeing in as products iCAD’s GE not of customers. of year AI on and systems, XD software a as in that market objective
market We to throughout this expect the continue remainder dynamic the beyond. of and year
our our is of Paralleling channels our sales infrastructure. through U.S. the direct using sales continuing tilt commercial expanded this trend
to delicate Our making successfully continued and that through this OEM products balance is can bolstering PACS in This while only goal is continue be partners iCAD a the approach, channels. available to brand. both implicated of the
which And this ProFound ensure effort underway is is ProFound we launch have months. Institute, brand will established. coming well We differentiation efforts the the of formally in at and that center to our concerted
and when be Institute AI choices how on focusing AI ProFound educational how the customers efforts, solutions can will to that expect education offering on our to position make making form through differentiate customer informed technology. an We decisions expansive
existing opportunity received Our had differentiation that inform Europe our CE for and while about common with cancer mammography advantages already only is cancer of AI the the among for have XD Europe the contains Mark lead. most substantial good accounts. for We customers upselling base our population, the announced Europe, X% than as it in With of providing has to European women. and just This is XX% – cancer as iCAD. ProFound global patients a being installed approval Europe. market ability important world’s opportunities innovation burden, unique in breast an more We recently of
as technology, opportunity deep earlier while AI to learning laid have We represent from some to create business, of many to new sites, of cases, technology, new therefore, an at XD an substantial XD or AI view in generations CAD offering. CAD, all, also move targeted XD no sites opportunity XD been our adopters ProFound
ProFound on QX. offerings. tomosynthesis, we were and XD in in received ProFound customer featured AI digital booth, XD SIFEM medical for current technology. as both iCAD highly ProFound XD exhibition so France tomosynthesis. AI now AI can breast to in with mammography, late AI We for upgrade the for AI commentary Europe, XD ProFound our for as well-attended deep-learning We ProFound has XD as much for current ProFound well opportunity as advanced customers introduced iCAD sales AI percent sell XD XD along and In AI feedback AI the new the at or mammography new positive important successfully conference
what we invest optimize of we call to are while Now business tomorrow. in the I of the are business now to working beginning today,
have imperative We at financing. recent least may to of one that any market. mammography technology a This for other AI our the ahead one strategic enter generation reason was be
assessment initiative robust predict the cancer what accelerate and into and movement effort detected. age-based reflects cancers realm initiatives emerge important of detection year, the began and currently breast move This are reflects under In addition of in to they we beyond risk in before is prediction. exciting a of model an building half to our the to planned to commercial infrastructure our able also our future first our the around cancer screening even efforts being
women researchers is emerging license more imaging. risk newly The of the screening risk consistent for predictions towards emerging greater allow Sweden. our Institute Stockholm, patients lead to with with with this Karolinska will way with at a Karolinska with foundation the agreement in individualized profile. to of exclusive This This is training, us capability frequent collaboration The trend model risk-adaptive
leading-edge addition XX to characteristics. we that. detection move will has are woman this capability regimens, a will risk with all genomic or over of software tools. This part mammography personalized own AI and and Each programming more profile, by refining effort, imaging more data assess unique radiomic we perhaps to treatment correlate AI enabled in our information As targeted towards iCAD risk and
anticipate and a accelerating risk the our that at a anticipate early XXXX. highly between what individual image on of in screening in development Chicago us. having We to the XXXX prediction, is coming risk will combines We work the releasing cancers XX intend market efforts December. XXXX the prediction area in the which other today we characteristics. in level months, regulatory after commercially and ability regimens. the ahead sophisticated age-based current of predictive is within interval focus of of on the some breast analysis area be XX no accurately There in have available the to product RSNA some in will product predict unveiling We of market the risk In to
and our prediction going in us risk breast shortly. in the investing portion care of June, of resulted proceeds. that focus which transforming this into in with successfully net risk our into the to million acceleration business, is of $X.X this will financing Other detection completed I are was funds going platform. which Therapy It led A discuss in promising raising
all grateful many to participated iCAD, in and We investors, support efforts. of continue financing to are the to this our new who
now last U.S. our detailed as Additionally, on targeted major geographic call, all complete essentially covered. sales we detection is our markets team with staffing
We dozen distribution the in the bolster continue parts efforts over other in States, also we’ll have and and United of outside Europe our to and countries world. distribution grow a
now and also training beginning we at the installation of in for market sales, Asian mammography than to place personnel, With newly added now commercial have AI. are exploring actively assess and doubled beginning the XXXX. we QX infrastructure had service, the more We
integrated both level. developed us and major national at of we’ve more to hospital a account and decision-makers resource capability on actively While recently sales team, key pursue a network will the and systems. group added the purchasing This we also allow call robust the customers commercial level, high-level economic new to delivery
regional sites sales We deployed economic enterprise-level the systems, capability a and clinical, stratified technical large large have essential at level, for accounts. national sales and higher which luminary is and to now volume care health
proliferation more personnel are health as continue may and As commercial resources of to densely grow add swiftly. cover sales care will new the areas as rapidly in AI well needed bolstering growing we move to areas to aggregate as capabilities populated facilities sales introduced, tend more additional and where
synchronize as way calls, of [Technical commercial the our need clocks describe Now buildout to to in our metaphor prior efforts. I Difficulty] used a the of three
sales synchronized We to presentation time one, licenses two, XXX- training process cycle and user the three, day and to within integrating XX- have the software complex installing now for: initial from reps; environments. close;
speed we in have done have economies using, We to approach. two as, three of what an quarters could four what refer taken quarters to only
the As are in benefits We to and sales and seeing Again, expenses appropriately the previously sales finally quarters and warrants direct and in high-margin in pipeline increased of ability our build-out to commercial to projected, will efforts, reported and we, we areas generate now ahead. accounts. and of demand the as we quarters. expanded customer clear revenue where expediently our service our add course, very expect sales operating to sell mindfully believe continue may resources we exceed recent
mid- than QX Therapy Thus, were up quarter therapy now XX% six ended QX volume includes Therapy sales for product compared At products products, tempered were sales stated June our to Therapy up X% the the were to first XX% future and lower recurring six segment. we last can first above our XX, new sales. sales sales XXXX products, QX total – therapy doubled for year the and revenues year’s lumpy, discuss months, first our like over half lead disposables shipments quite product X% were over I’d recurring Xoft that sales. were Total which midyear, can over were total and QX of large sales, XXXX. last product year. virtually to which sales revenue, be months by all XXXX. up sales and
In In likely. We oncology model, acceleration date radiation implemented, choose been radiation new the if or later high-quality, a model and encouraging IORT for have radiation CMS according long potentially to a bundled the proposed incentivizes a there CMS, July, model item Xoft a as this would is to the XXXX payment which forward which impact on area We gating adoption look dramatic recently be effective care, considerably the to providers that Xoft CMS payment proposed are April. which, developments. cost- therapy implementation as January of oncology. place explicitly of of for favorable early could very products, as business. in potential more in early see of reimbursement,
oncology that in care procedure prove can level and building value technologies procedure CMS clinical referential weeks. radiation over procedures demonstrates occur rather with take duration. This for the external quite single as of beam the over when could a rule places is model therapy outcomes equivalent to very days we procedure or single our months of bit This model In clinical is, care common anticipate IORT playing volume ahead. many procedure upon. proposed a new even data radiation the subject a single-fraction, therefore, sum, XX-minute field – compared procedures weeks. important that of period, effective Recently The as study the anticipate published that that jockeying data XX-day and we of
team. economics of to our area capability Associated with use of important was timely hiring of recent addition overall this securing funds important another in from development, in-house our and the CMS the and an reimbursement well as expertise This financing of is the the care. as
the to the more would half funded, aspects at rate being the into that in be business, Xoft market Other the significantly allow and accelerating now second are now technologies moving of XXXX. of which released are
in us Treatments Our rectal track. applicated accelerate June are now financing opportunities allowed cancers for several new for glioblastoma Xoft. has to and on growth an accelerated development
now applications Although of catalyze do clinical Xoft use indications. and to cleared new now under the adoption the need these applicators studies and the throughout FDA safety for for efficacy development we products body, are the
as gynecology product will cancer and essential The indications. both our brain extensions skin additional offering beyond of and take applicators for our and rectal platform. see We these logical advocators current us and cancer breast, indications
more exceedingly and that large the growth is platform radiation radiation of prostatectomies, cancer. or new of surgery thereby and therapy This prostate extension as therapy traditional one could done delivered surgical than concept our breast be nonshielded Xoft may market. the the versus same real-time an weeks room an in of have incremental use in where during opportunity represent during days for in therapy delivering current We radiation of be surgery, a additional would so robotic course and cancer minutes
and Clinical is use underway. already product trials testing
site robot at now world-renowned as surgery XX% to has following much top our patients balloon, radical surgeon, week, we more radiation physician progress who have time prostatectomy we proceed and the trained According has surveyed, robotic done anyone fellows are and we the of large its therapy XX% over are treatment a of potential designed we testing coming last significant fact, started as surgeons with this combined world. quarters. with Florida the procedure. in real- studies than same-day who could working In and prostatectomies with treatment a robotics benefit just from a and as to newly dozens Vinci luminary in This da
potential and more therapy formation indications. potentially Again, U.S. larger has result multidisciplinary and advisory our our an locations, – absorbs impact for human-use accelerate than finding has radiation prostate prostate and to size allowed trials recent expanded The – in surgeons, allowed of intraoperation comprised physicists. be a IORT studies us multiple at and funding could oncologists of the to current us cancer both OUS this of and in accelerate clinical and radiation board high- level will sites, recent
We to are now. separate starting
is Xoft sum, clinical core applications. to technology extensible that a In significantly other is
that product with and bit around to XX applications luminary months the possible us to rectal, Our targeted brain market, the will earlier. take a to XX estimates beta current get globe are sites launches to
initiatives range of Xoft scalable. with a capabilities these as core enormously a of are position treatment All technology that provider
the Xoft in beyond, and these and to XXXX in developments to we bring that opportunities about the to introduction applicators envision of CMS we’ll offerings the these know investing have capital present market. achieve late adequate with Between upside XXXX. are somewhat It more QX as the this of know new in We business, now QX towards are be results that of particularly the more year. after latter achieved the upward we torque aforementioned perhaps earlier possible indications but growth is look a before these a could part launched, only we as CMS about and
On the XXXX, intrinsic the and our team of first call, about hidden in our we earnings delivered spoke iCAD following QX releasing new executive goal of value by technologies.
vision combined With iCAD’s growth core now of study both the execution will take the as and recent promising value beginning It now we our mentioned time we but frame of business, in releasing technologies Therapy, diligence inherent Detection intense capabilities with and we characterize businesses. further intrinsic goal accelerate of focus, core operations the in technologies. therapy the to our can our and above: are realize to the believe previously financing, stated
these can on specific some programs, with Now over turn so now and Scott? highlighted he financial provide comprehensive call review to actions comments the a more I results. our financials, of will Scott,
